NextPharma agrees partnership with Bone Therapeutics
Will develop a sterile investigational product at its Belgian plant
NextPharma, a European provider of product development, contract manufacturing and cold chain and logistics outsourcing services, has entered into a partnership with Bone Therapeutics, a bone cell therapy company based in Belgium, Université Libre de Bruxelles (ULB) and Université de Liège (ULg). BioWin, the Health Cluster of Wallonia, in Belgium, will oversee the partnership.
The collaboration involves the development of Bone Therapeutics products for the treatment of osteo-articular diseases combining anti-inflammatory compounds and viscoelastic scaffolds.
The first product will be a sterile depot (sustained release) formulation in pre-filled syringes for intra-articular administration.
NextPharma will carry out product development and manufacture of this sterile investigational medicinal product in pre-filled syringes at its Sterile Product Development Centre in Belgium and laboratory work has already begun.
Successful clinical trials will result in the product’s commercial manufacture at NextPharma’s commercial scale sterile manufacturing facility on the same site.
Sean Marett, managing director, NextPharma Technologies, Product Development Services (PDS), said: ‘This work provides NextPharma with a great opportunity to demonstrate our investigational medicinal product development and manufacturing skills in pre-filled syringes as well as our ability to scale-up from clinical trials to commercial scale quantities of the product at our Braine-l’Alleud site in Belgium in due course.’